Bank of America’s Unity Biotechnology UBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-160
| Closed | -$62 | – | 8697 |
|
|
2025
Q2 | $62 | Buy |
160
+28
| +21% | +$24 | ﹤0.01% | 8057 |
|
|
2025
Q1 | $137 | Buy |
132
+5
| +4% | +$9 | ﹤0.01% | 7768 |
|
|
2024
Q4 | $124 | Buy |
127
+1
| +0.8% | +$1 | ﹤0.01% | 7694 |
|
|
2024
Q3 | $185 | Buy |
126
+1
| +0.8% | +$1 | ﹤0.01% | 7587 |
|
|
2024
Q2 | $169 | Buy |
+125
| New | +$190 | ﹤0.01% | 7596 |
|
|
2024
Q1 | – | Sell |
-8
| Closed | -$15 | – | 8202 |
|
|
2023
Q4 | $15 | Buy |
+8
| New | +$15 | ﹤0.01% | 7711 |
|
|
2023
Q2 | – | Sell |
-7
| Closed | -$11 | – | 7954 |
|
|
2023
Q1 | $11 | Sell |
7
-29
| -81% | -$116 | ﹤0.01% | 7621 |
|
|
2022
Q4 | $98 | Buy |
36
+28
| +350% | +$81 | ﹤0.01% | 7674 |
|
|
2022
Q3 | $0 | Sell |
8
-8,681
| -100% | -$54.8K | ﹤0.01% | 8207 |
|
|
2022
Q2 | $49K | Buy |
8,689
+8,671
| +48,172% | +$72.3K | ﹤0.01% | 6838 |
|
|
2022
Q1 | $0 | Sell |
18
-3,588
| -100% | -$40.3K | ﹤0.01% | 8770 |
|
|
2021
Q4 | $53K | Sell |
3,606
-8,062
| -69% | -$176K | ﹤0.01% | 7191 |
|
|
2021
Q3 | $350K | Buy |
11,668
+3,362
| +40% | +$119K | ﹤0.01% | 5901 |
|
|
2021
Q2 | $385K | Sell |
8,306
-3,209
| -28% | -$155K | ﹤0.01% | 5624 |
|
|
2021
Q1 | $691K | Sell |
11,515
-156
| -1% | -$10.6K | ﹤0.01% | 5132 |
|
|
2020
Q4 | $612K | Buy |
11,671
+6,604
| +130% | +$318K | ﹤0.01% | 4865 |
|
|
2020
Q3 | $176K | Buy |
5,067
+616
| +14% | +$39K | ﹤0.01% | 5373 |
|
|
2020
Q2 | $386K | Buy |
4,451
+2,110
| +90% | +$156K | ﹤0.01% | 4802 |
|
|
2020
Q1 | $135K | Sell |
2,341
-9
| -0.4% | -$567 | ﹤0.01% | 5340 |
|
|
2019
Q4 | $169K | Sell |
2,350
-335
| -12% | -$23.6K | ﹤0.01% | 5725 |
|
|
2019
Q3 | $164K | Buy |
2,685
+403
| +18% | +$28.5K | ﹤0.01% | 5780 |
|
|
2019
Q2 | $217K | Sell |
2,282
-44
| -2% | -$3.74K | ﹤0.01% | 5573 |
|
|
2019
Q1 | $189K | Buy |
2,326
+504
| +28% | +$57.2K | ﹤0.01% | 5551 |
|
|
2018
Q4 | $297K | Buy |
1,822
+1,689
| +1,270% | +$224K | ﹤0.01% | 5254 |
|
|
2018
Q3 | $22K | Buy |
133
+43
| +48% | +$7.08K | ﹤0.01% | 6489 |
|
|
2018
Q2 | $13K | Buy |
+90
| New | +$13.2K | ﹤0.01% | 6605 |
|
Other funds holding UBX
XT
SPIA
AIP
AWM
Bank of America's UBX Position: Q3 2025 in Review
Bank of America sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 160 shares — an estimated $62 sold.
Bank of America first reported a position in UBX in Q2 2018 and held it in 26 quarters. The position peaked at $691K in Q1 2021. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.
- Bank of America reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 160 Unity Biotechnology shares in Q3 2025, an estimated $62.
- Bank of America first reported a position in Unity Biotechnology in Q2 2018 and held it in 26 quarters.
- Bank of America's Unity Biotechnology position peaked at $691K in Q1 2021.
- 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.